Piñeiro PD, Madrigal BG, Domínguez CJ, Rodríguez MN, Hernández PJC

Language: Spanish
References: 8
Page:
PDF size: 90.26 Kb.

ABSTRACT

With the contemporary rise of new paradigms in medical sciences, such as personalized Medicine, a more effective oncological resection is sought: with new surgical margins according to the tumor stage. The biotechnological advances in Cuba have allowed the development of leading drugs in the word, like Nimotuzumab, a monoclonal antibody against the receptor of epidermal grow factor. This receptor is highly expressed in several malignant tumors of epithelial origin. By labeled it with a radioisotope can help the surgeon in the precise determination of the tumor extension (radiolabeled) of these neoplasms during the surgical act.

REFERENCES

1. Mortalidad. En: Zaca Peña E, editor. Anuario estadístico de salud 2010. La Habana: Dirección nacional de registros médicos y estadísticas de salud del Ministerio de Salud Pública; 2017.

2. Zaca Peña E. Mortalidad. Anuario Estadístico de Salud 2010.

3. Van de Velde CJH, Boelens PG, Borras JM, Coebergh JW, Cervantes A, Blomqvist L, Betts-Tan RGH et al. EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum. Eur.J.Cancer. 2014 Jan; 50(1): 1.e1-1.e34.

4. Kaur S, Venktaraman G, Jain M, Senapati S, Garg PK, Batra SK. Recent trends in antibody-based oncologic imaging. Cancer.Lett. 2012 Feb 28;315(2):97-111

5. Tsuchimochi M, Hayama K. Intraoperative gamma cameras for radioguided surgery: Technical characteristics, performanceparameters, and clinical applications. Phys.Med. 2013 Mar; 29(2):126-138.

6. Aitken DR, Hinkle GH, Thurston MO. A gamma detecting probe for radioimmune detection of CEA producing tumors. Successful experimental use and clinicalcase report. Dis.Colon.Rectum. 1984 May; 27(5): 279–82.

7. Tiernan J P, Ansari I, Hirst NA, Millner PA, Hughes TA, Jayne DG. Intra-operative tumour detection and staging in colorectalcancer surgery. Colorectal Dis. 2012 Sep;14(9):e510-20.

8. Torres LA, Perera A, Batista JF, Hernandez A, Crombet T, Ramos M, Neninger E et al. Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin. Nucl.Med.Commun. 2005 Dec;26(12):1049.